- Home
- WFRD vs LNTH Comparison
WFRD vs LNTH Comparison
Compare WFRD & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- LNTH
- Stock Information
- Founded
- WFRD 1941
- LNTH 1956
- Country
- WFRD United States
- LNTH United States
- Employees
- WFRD N/A
- LNTH N/A
- Industry
- WFRD Metal Fabrications
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WFRD Industrials
- LNTH Health Care
- Exchange
- WFRD Nasdaq
- LNTH Nasdaq
- Market Cap
- WFRD 7.9B
- LNTH 7.2B
- IPO Year
- WFRD N/A
- LNTH 2015
- Fundamental
- Price
- WFRD $85.32
- LNTH $87.32
- Analyst Decision
- WFRD Strong Buy
- LNTH Strong Buy
- Analyst Count
- WFRD 8
- LNTH 7
- Target Price
- WFRD $148.25
- LNTH $121.86
- AVG Volume (30 Days)
- WFRD 957.0K
- LNTH 1.5M
- Earning Date
- WFRD 10-22-2024
- LNTH 11-06-2024
- Dividend Yield
- WFRD 1.17%
- LNTH N/A
- EPS Growth
- WFRD 51.37
- LNTH 304.57
- EPS
- WFRD 7.14
- LNTH 6.02
- Revenue
- WFRD $5,534,000,000.00
- LNTH $1,496,799,000.00
- Revenue This Year
- WFRD $11.61
- LNTH $19.56
- Revenue Next Year
- WFRD $3.21
- LNTH $6.32
- P/E Ratio
- WFRD $11.93
- LNTH $14.50
- Revenue Growth
- WFRD 11.08
- LNTH 24.15
- 52 Week Low
- WFRD $77.00
- LNTH $50.20
- 52 Week High
- WFRD $135.00
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- WFRD 50.36
- LNTH 41.17
- Support Level
- WFRD $80.99
- LNTH $75.00
- Resistance Level
- WFRD $91.82
- LNTH $118.21
- Average True Range (ATR)
- WFRD 3.06
- LNTH 5.60
- MACD
- WFRD 0.23
- LNTH -0.66
- Stochastic Oscillator
- WFRD 52.06
- LNTH 28.51
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.